AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Amgen(AMGN) Prnewswire·2024-10-15 12:00MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ PatientsFirst and Only Phase 3 Placebo-Controlled gMG Trial for a Biologic That Tapered Corticosteroid UseTHOUSAND OAKS, Calif., Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of adults with generalized myasthenia gravis (gMG), a ...